FETAL DOPAMINE CELLS--IMPROVING GRAFT VIABILITY

胎儿多巴胺细胞——提高移植物活力

基本信息

  • 批准号:
    6112264
  • 负责人:
  • 金额:
    $ 20.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-05-01 至 2002-04-30
  • 项目状态:
    已结题

项目摘要

One of the foremost difficulties with the application of neural transplantation to the treatment of neurodegenerative disorders is enhancing the survival of grafted donor tissue to ensure that adequate amounts of dopamine are produced and that transplant effect are long- lasting. One prominent laboratory reported that the survival rate of grafted, human dopamine neurons is as low as 2-5% using current techniques, tested in rodents. This laboratory and others have used this conclusion as the basis for substantially increasing the amount of tissue implanted in clinical experiments. We have been able to achieve a considerably higher survival rate in primates by studying factors which might enhance it. Improved survival of grafts may be achieved from tissue obtained from a critical stage of dopamine neurogenesis. It may be noteworthy that clinical experiments have utilized a much wider range of gestational ages than would be suggested from our new data. Moreover, we have found that chronically administered levodopa in rodents results in grafts with stunted dopamine neurons and diminished behavioral improvement. Other factors related to the preparation and storage of the donor tissue or pharmacological treatments after grafting may be equally important. Although some studies performed in rat may provide useful clues, it is understood that the greater size and complexity of the monkey brain and its similarity to the human brain makes it essential to optimize the viability of grafts in monkey models. Variables to be studied include the age of the donor tissue, graft survival over time, the method of preparation of the donor tissue such as cell suspension, solid grafts, and cryopreservation, and the effects of conventional pharmacotherapies such as levodopa, deprenyl and others on graft survival. These studies will be carried out using grafts of mesencephalic tissue into monkeys over several time periods, controlling for fetal age, matched comparisons of suspended vs. small solid grafts implanted on opposite sides of the caudate nucleus of the same monkey, fresh vs. cryopreserved tissue also implanted on opposite sides of the brain. Pharmacological studies will be done first in primate cell cultures and, if positive, subsequent experiments will test these effects on grafted monkeys. This project also will examine the effectiveness of grafts of embryonic striatum to promote growth of neurites from co-grafted mesencephalic tissue as a means of achieving greater outgrowth from grafted neurons. During the current award period we also discovered that striatal grafts have a growth enhancing effect on the host brain that can result int he growth of tyrosine hydroxylase positive fibers into grafts placed into the dorsolateral striatum. We will examine this phenomenon from the perspective of early intervention designed at protecting the residual host dopaminergic neurons.
应用神经网络的最大困难之一 移植治疗神经退行性疾病的方法是 提高移植供体组织的存活率,以确保足够的 产生大量的多巴胺,移植效果持久 持久。 一个著名的实验室报告称, 使用现有技术,移植的人类多巴胺神经元含量低至 2-5%, 在啮齿动物身上进行了测试。 本实验室和其他实验室已将此结论用作 大幅增加植入组织数量的基础 临床实验。 我们已经能够实现相当高的存活率 通过研究可能增强它的因素来研究灵长类动物。 提高生存率 移植物可以从关键阶段获得的组织来实现 多巴胺神经发生。 值得注意的是,临床实验 使用的胎龄范围比建议的范围大得多 从我们的新数据来看。 此外,我们还发现,长期服用 啮齿类动物的左旋多巴会导致移植物多巴胺神经元发育不良 行为改善减弱。 与此相关的其他因素 供体组织的准备和储存或药物治疗 嫁接后可能同样重要。 尽管一些研究进行了 在大鼠中可能提供有用的线索,据了解,较大的体型和 猴脑的复杂性及其与人脑的相似性使得 优化猴子模型中移植物的活力至关重要。 要研究的变量包括供体组织的年龄、移植物存活率 随着时间的推移,制备供体组织(例如细胞)的方法 悬浮液、固体移植物和冷冻保存,以及它们的影响 常规药物治疗,如左旋多巴、丙炔苯丙胺等 移植物存活。 这些研究将使用移植物进行 中脑组织经过几个时间段进入猴子体内,控制 对于胎儿年龄,悬浮移植物与小型实体移植物的匹配比较 植入同一只猴子尾状核的两侧, 新鲜组织与冷冻组织也分别植入到组织的两侧 脑。 药理学研究将首先在灵长类细胞培养物中进行 如果阳性,后续实验将测试这些对嫁接的影响 猴子。 该项目还将检查胚胎移植的有效性 纹状体促进共移植中脑组织神经突的生长 作为实现移植神经元更大生长的一种手段。 期间 当前奖励期间我们还发现纹状体移植物具有生长 增强对宿主大脑的影响,从而导致生长 将酪氨酸羟化酶阳性纤维放入移植物中 背外侧纹状体。 我们将从以下方面来考察这一现象: 旨在保护残留宿主的早期干预的观点 多巴胺能神经元。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN RICHARD SLADEK其他文献

JOHN RICHARD SLADEK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN RICHARD SLADEK', 18)}}的其他基金

Nigrostriatal Tract Reconstruction
黑质纹状体束重建
  • 批准号:
    7764644
  • 财政年份:
    2009
  • 资助金额:
    $ 20.03万
  • 项目类别:
Nigrostriatal Tract Reconstruction
黑质纹状体束重建
  • 批准号:
    8056228
  • 财政年份:
    2009
  • 资助金额:
    $ 20.03万
  • 项目类别:
9th Internatl Meeting on Neural Transplantation & Repair
第九届国际神经移植会议
  • 批准号:
    6944557
  • 财政年份:
    2005
  • 资助金额:
    $ 20.03万
  • 项目类别:
Nigral targeting strategies for neural function restora
神经功能恢复的黑质靶向策略
  • 批准号:
    6824647
  • 财政年份:
    2003
  • 资助金额:
    $ 20.03万
  • 项目类别:
Enhancement Of IRB Technology, Education and Facilities
加强IRB技术、教育和设施
  • 批准号:
    6591643
  • 财政年份:
    2002
  • 资助金额:
    $ 20.03万
  • 项目类别:
Enhancement of IRB Education & Technology
加强IRB教育
  • 批准号:
    6781663
  • 财政年份:
    2002
  • 资助金额:
    $ 20.03万
  • 项目类别:
CORE--MORPHOLOGY AND TISSUE CULTURE
核心——形态学和组织培养
  • 批准号:
    6112267
  • 财政年份:
    1999
  • 资助金额:
    $ 20.03万
  • 项目类别:
FETAL DOPAMINE CELLS--IMPROVING GRAFT VIABILITY
胎儿多巴胺细胞——提高移植物活力
  • 批准号:
    6273752
  • 财政年份:
    1998
  • 资助金额:
    $ 20.03万
  • 项目类别:
CORE--MORPHOLOGY AND TISSUE CULTURE
核心——形态学和组织培养
  • 批准号:
    6273755
  • 财政年份:
    1998
  • 资助金额:
    $ 20.03万
  • 项目类别:
CORE--MORPHOLOGY AND TISSUE CULTURE
核心——形态学和组织培养
  • 批准号:
    6243600
  • 财政年份:
    1997
  • 资助金额:
    $ 20.03万
  • 项目类别:

相似海外基金

Development and Translation Mass Spectrometry Methods to Determine BioMarkers for Parkinson's Disease and Comorbidities
确定帕金森病和合并症生物标志物的质谱方法的开发和转化
  • 批准号:
    2907463
  • 财政年份:
    2024
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Studentship
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
  • 批准号:
    MR/Y019415/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Research Grant
Promoting Parkinson's disease trial participation in rural and coastal communities
促进农村和沿海社区参与帕金森病试验
  • 批准号:
    2898794
  • 财政年份:
    2024
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Studentship
The Diagnostic and Prognostic Utility of Eye Tracking in Parkinson's Disease and Related Disorders
眼动追踪在帕金森病及相关疾病中的诊断和预后效用
  • 批准号:
    479285
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Operating Grants
Neurophysiological mechanism underlying freezing of gait in Parkinson's disease: transcutaneous spinal cord stimulation for gait disturbance
帕金森病步态冻结的神经生理机制:经皮脊髓刺激治疗步态障碍
  • 批准号:
    23K10409
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Inhibition of cell-to-cell propagation of alpha-synuclein aggregation by glial cells and its involvement in neuropathology in Parkinson's disease.
神经胶质细胞抑制α-突触核蛋白聚集的细胞间传播及其参与帕金森病的神经病理学。
  • 批准号:
    23K06928
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Propagation of a-synuclein in Parkinson's disease progress
α-突触核蛋白在帕金森病进展中的传播
  • 批准号:
    22KJ2095
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Drug-microbiome-host interactions in Parkinson's disease
帕金森病的药物-微生物组-宿主相互作用
  • 批准号:
    2881438
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Studentship
Ordering the disordered in Parkinson's disease to derive peptide inhibitors of alpha-synuclein toxicity
命令帕金森病患者衍生出α-突触核蛋白毒性的肽抑制剂
  • 批准号:
    2884235
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Studentship
MICA: How does the pedunculopone nucleus influence treatment responses in Parkinson's disease, and can it be targeted for new treatment strategies
MICA:脚核如何影响帕金森病的治疗反应,是否可以作为新治疗策略的目标
  • 批准号:
    MR/X005267/1
  • 财政年份:
    2023
  • 资助金额:
    $ 20.03万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了